148 related articles for article (PubMed ID: 19203530)
1. Preface. Combining clinical, translational and basic cancer drug research: the 2008 CESAR annual meeting.
Brockmoeller J; Sehrt D; Scheulen ME
Int J Clin Pharmacol Ther; 2009 Jan; 47(1):30-2. PubMed ID: 19203530
[No Abstract] [Full Text] [Related]
2. 10 Years CESAR Anticancer Drug Research - The 7th CESAR Annual Meeting 2009. Preface.
Edler L; Sehrt D; Scheulen ME
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):435-9. PubMed ID: 20557836
[No Abstract] [Full Text] [Related]
3. MedGenMed Hematology/Oncology conference report--translational research: any danger lurking in its wake? Highlights from the 2003 annual meeting of the American Association for Cancer Research; July 11-14, 2003; Washington, DC.
Mariani SM
MedGenMed; 2003 Aug; 5(3):34. PubMed ID: 14600670
[No Abstract] [Full Text] [Related]
4. Standard Operating Procedures for clinical trials of the CESAR Central European Society for Anticancer Drug Research--EWIV. Preface.
Gastl G; Dittrich C
Onkologie; 2003 Oct; 26 Suppl 6():IX. PubMed ID: 23570176
[No Abstract] [Full Text] [Related]
5. Editorial. Approaches to personalized medicine in oncology--the 9th Annual Meeting of CESAR in Greifswald.
Ritter C; Sehrt D; Jaehde U
Int J Clin Pharmacol Ther; 2012 Jan; 50(1):53-4. PubMed ID: 22192647
[No Abstract] [Full Text] [Related]
6. American Association for Cancer Research--100th Annual Meeting. New therapeutic developments: part 1. 18-22 April 2009, Denver, CO, USA.
Gale S; McGee V; Lee W
IDrugs; 2009 Jun; 12(6):331-4. PubMed ID: 19517308
[No Abstract] [Full Text] [Related]
7. American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 2.
Walker K
IDrugs; 2007 Aug; 10(8):517-9. PubMed ID: 17665321
[No Abstract] [Full Text] [Related]
8. Cancer Clinical Trials: The Rear-View Mirror and the Crystal Ball.
Cescon D; Siu LL
Cell; 2017 Feb; 168(4):575-578. PubMed ID: 28187280
[TBL] [Abstract][Full Text] [Related]
9. Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.
Venkatakrishnan K; Ecsedy JA
Clin Pharmacol Ther; 2017 Jan; 101(1):99-113. PubMed ID: 27804123
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?
Bell IM
J Med Chem; 2004 Apr; 47(8):1869-78. PubMed ID: 15055985
[No Abstract] [Full Text] [Related]
11. Epidermal growth factor receptor inhibitors: current status and future directions.
Chen HX; Cleck JN; Coelho R; Dancey JE
Curr Probl Cancer; 2009; 33(4):245-94. PubMed ID: 20082842
[No Abstract] [Full Text] [Related]
12. Learning from exceptional drug responders.
Mullard A
Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081
[No Abstract] [Full Text] [Related]
13. [Situation of translational research and development of molecular-targeted agents for multiple myeloma].
Kizaki M
Nihon Rinsho; 2007 Dec; 65(12):2357-61. PubMed ID: 18069283
[TBL] [Abstract][Full Text] [Related]
14. American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 1.
Walker K; Kibble A; Shumoogam J
IDrugs; 2007 Aug; 10(8):513-6. PubMed ID: 17665320
[No Abstract] [Full Text] [Related]
15. American Association for Cancer Research--96th Annual Meeting. Anticancer agents-part I.
Phillips T; Collins T; Davies J
IDrugs; 2005 Jun; 8(6):443-5. PubMed ID: 15906182
[No Abstract] [Full Text] [Related]
16. Advances in cancer drug discovery - a British association for cancer research meeting.
Westwell AD
IDrugs; 2008 Nov; 11(11):783-6. PubMed ID: 18988118
[TBL] [Abstract][Full Text] [Related]
17. American Association for Cancer Research--100th Annual Meeting. New therapeutic developments: part 2. 18-22 April 2009, Denver, CO, USA.
Gale S; McGee V; Lee W
IDrugs; 2009 Jun; 12(6):335-8. PubMed ID: 19517309
[No Abstract] [Full Text] [Related]
18. SOP 01: Clinical investigations in CESAR.
Onkologie; 2003 Oct; 26 Suppl 6():1-4. PubMed ID: 23570177
[No Abstract] [Full Text] [Related]
19. Cross-boundary cancer studies at the University of Tokyo: Opening a path through research to the future of cancer treatment.
Noda T
Jpn J Clin Oncol; 2014 Feb; 44 Suppl 1():i43-47. PubMed ID: 24516212
[No Abstract] [Full Text] [Related]
20. Extended abstracts of the annual meeting of the Working Group for Pharmacology in Oncology and Hematology (APOH) of the Central European Society for Anticancer Drug Research (CESAR), Vienna, Austria, 2005.
Int J Clin Pharmacol Ther; 2005 Dec; 43(12):566-608. PubMed ID: 16625725
[No Abstract] [Full Text] [Related]
[Next] [New Search]
